Inaugural MCI Masterclass 2021

Break through the burden of CMPA

MCI Masterclass

This Australia-first event led by Associate Professor Michael Woodward and Associate Professor Mark Yates brought together leading experts to present the latest evidence and insights on Driving Change in the early identification and management of patients with mild cognitive impairment.

Sign up now for session recordings

Patient resources

Souv-connections-memory-hub

Souvenaid® Info hub

Patients and carers can learn more about Souvenaid, Alzheimer's Disease, mild cognitive impairment and brain health in one convenient place.
Learn more Learn more about Souvenaid
screening-tool

Cognitive Impairment Screening Tool

Download a cognitive impairment screening tool to help determine whether your patient’s memory loss could be part of natural aging or something else such as Mild Cognitive Impairment or Dementia. This simple screening tool, developed by Dr Philip Morris and Associate Professor Michael Woodward AM can help to identify patients who warrant further investigation via a series of simple questions.
Download here

Souvenaid® range

Memory-hub-Souvenaid-Liquid-Range
Souvenaid® liquid
Powered by Fortasyn Connect®, a unique combination of nutrients formulated to support the growth of brain connections. Available in 3 delicious flavors, Vanilla, Cappuccino, and Strawberry, in ready-to-drink single serve 125ml bottles.
View Product Request product for evaluation

Memory Expert resources

CMPA Patient Case Studies

APP 2022 Conference Lecture - Mild Cognitive Impairment, what pharmacists need to know.

In this lecture, recorded at the APP Conference in March 2022, Associate Professor Michael Woodward, Geriatrician & Director at Aged Care Research, Austin Health, shares his expert knowledge on Mild Cognitive Impairment.
Learn more
CMPA Clinical Papers

Early signs of Alzheimer’s disease

Alzheimer’s disease is a complex condition that often starts to develop decades before symptoms appear. In the early stages, specific regions in the brain, crucial for memory, are affected causing frequency and severity of memory lapses.
Learn more
Break through the burden of CMPA

The role of Souvenaid® in the management of patients with early Alzheimer’s disease.

Associate Professor Michael Woodward gives a 5 minute lecture on the evidence for the medical food Souvenaid® and its role in the management of patients with early Alzheimer’s disease including mild cognitive impairment.

Learn more
MCI causes cognitive changes that are serious enough to be noticed by the person affected and by family and friends.

Understanding Mild Cognitive Impairment (MCI)

MCI causes cognitive changes that are serious enough to be noticed by the person affected and by family and friends.1 It is estimated that people with MCI have a 3 to 5 times increased risk of developing dementia and yet it can be challenging to differentiate MCI from normal ageing.2

Learn more